EUCTR2005-005194-30-GB进行中（未招募）1 期
A multi-centre, randomised, double-blind, placebo controlled, parallel group exploratory study to investigate the efficacy, safety and tolerability of AD 337 in the treatment of fibromyalgia in female subjects.
Arakis Ltd.0 个研究点目标入组 200 人开始时间: 2006年3月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subjects who meet all the following criteria will be eligible to participate in the study:
- •Female subjects.
- •Subjects aged 18 - 65 years.
- •Subjects who meet ACR 1990 criteria for the classification of fibromyalgia and have a history of widespread musculoskeletal pain for at least 3 months. Subjects who have pain in 11 or more of 18 tender point sites on digital palpation.
- •Subjects who are able and willing to discontinue central nervous system active therapies, including antidepressants; sedative-hypnotic agents; muscle relaxants and centrally-acting analgesics during the study.
- •Subjects who are able to read, speak and understand English, capable of understanding the study requirements. and willing to cooperate with the study instructions.
- •Subjects who are able and willing to provide written informed consent.
- •Subjects who complete the FIQ questionnaire at visit 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who are pregnant or breast feeding or unable or unwilling to use an adequate method of contraception as defined by the protocol.
- •Subjects whose primary pain originates from traumatic injury.
- •Subjects with concurrent inflammatory diseases including rheumatic disease, rheumatoid arthritis and inflammatory arthritis; hypothyroidism, hyperparathyroidism, autoimmune disease or unstable metabolic disease.
- •Subjects with current or recent history of psychosis, hypomania, mania, dementia or other serious psychiatric disorder which, in the opinion of the investigator, would make then unsuitable to participate in the study.
- •Subjects with an average QTc. interval greater than 470ms at their screening visit.
- •Evidence of alcohol or substance abuse by the subject in past 6 months.
- •Use of an investigational drug within 30 days of the subject's screening visit.
- •Subjects who are intolerant to serotonin and noradrenaline reuptake inhibitors (SNRIs) or nefopam.
- •Subjects with clinically significant condition(s) such as (but not limited to) convulsive disorders, stroke, cardiac arrhythmia or cancers (all), that in the opinion of the Investigator, may compromise their safety or compliance, interfere with evaluation, or preclude completion of the study.
- •Subjects with a history of glaucoma or urinary retention.
- •Subjects with serum creatinine >1.5 x upper limit of normal [ULN] or liver function tests > 3 x ULN or other abnormal laboratory values at screening which indicates an underlying unknown concomitant disease that requires further evaluation.
- •Subjects who have failed to respond to 2 or more adequate regimens of 2 different classes of antidepressants for depression or fibromyalgia.
研究者
相似试验
进行中（未招募）
4 期
Aspirin for the prevention of cognitive decline in the Elderly: a Neuro-Vascular Imaging Study (ENVIS-ion), a sub-study of ASPirin in Reducing Events in the Elderly (ASPREE)ACTRN12609000613202Australian National University (ANU)600
已完成
不适用
A multi-centre, randomised, double-blind, placebo controlled clinical trial examining the efficiency and safety of multi-vitamin therapy in secondary stroke preventioCardiovascularCirculatory SystemStrokeISRCTN74743444niversity of Glasgow and Greater Glasgow Health Board (UK)8,000
进行中（未招募）
不适用
A multi-centre, randomized, double-blind, placebo controlled, multiple-dose, 4-way cross-over study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol salts (maleate, xinafoate and acetate) in patients with persistent asthma.persistent asthmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2009-010589-46-FRovartis Pharma Services AG32
进行中（未招募）
不适用
A multi-centre, randomized, double-blind, placebo controlled, multiple-dose, 4-way cross-over study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol salts (maleate, xinafoate and acetate) in patients with persistent asthmapersistent asthmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2009-010589-46-DEovartis Pharma Services AG32
进行中（未招募）
1 期
A randomised, double-blind, multi-centre, placebo controlled parallel group study to evaluate the efficacy and tolerability of a new Ibuprofen gel in patients with acute sports-related traumatic blunt soft tissue injury/contusion. - Project BRONSON efficacy trial.EUCTR2009-018017-40-DEReckitt Benckiser Healthcare UK Ltd